Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 244

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study

Open access
Stattin, P., Holmberg, E., Johansson, J.-E., Holmberg, L., Adolfsson, J., Hugosson, J., on behalf of the National Prostate Cancer Register (NPCR) of Sweden · 2010 · JNCI Journal of the National Cancer Institute

Abstract

BACKGROUND: Treatment for localized prostate cancer remains controversial. To our knowledge, there are no outcome studies from contemporary population-based cohorts that include data on stage, Gleason score, and serum levels of prostate-specific antigen (PSA). METHODS: In the National Prostate Cancer Register of Sweden Follow-up Study, a nationwide cohort, we identified 6849 patients aged 70 years or younger. Inclusion criteria were diagnosis with local clinical stage T1-2 prostate cancer from January 1, 1997, through December 31, 2002, a Gleason score of 7 or less, a serum PSA level of less than 20 ng/mL, and treatment with surveillance (including active surveillance and watchful waiting, n = 2021) or curative intent (including radical prostatectomy, n = 3399, and radiation therapy, n = 1429). Among the 6849 patients, 2686 had low-risk prostate cancer (ie, clinical stage T1, Gleason score 2-6, and serum PSA level of <10 ng/mL). The study cohort was linked to the Cause of Death Register, and cumulative incidence of death from prostate cancer and competing causes was calculated. RESULTS: For the combination of low- and intermediate-risk prostate cancers, calculated cumulative 10-year prostate cancer-specific mortality was 3.6% (95% confidence interval [CI] = 2.7% to 4.8%) in the surveillance group and 2.7% (95% CI = 2.1% to 3.45) in the curative intent group. For those with low-risk disease, the corresponding values were 2.4% (95% CI = 1.2% to 4.1%) among the 1085 patients in the surveillance group and 0.7% (95% CI = 0.3% to 1.4%) among the 1601 patients in the curative intent group. The 10-year risk of dying from competing causes was 19.2% (95% CI = 17.2% to 21.3%) in the surveillance group and 10.2% (95% CI = 9.0% to 11.4%) in the curative intent group. CONCLUSION: A 10-year prostate cancer-specific mortality of 2.4% among patients with low-risk prostate cancer in the surveillance group indicates that surveillance may be a suitable treatment option for many patients with low-risk disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djq154

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 244

Metadata

Authors
Stattin, P., Holmberg, E., Johansson, J.-E., Holmberg, L., Adolfsson, J., Hugosson, J., & Sweden, O. B. O. T. N. P. C. R. (. O.
Venue
JNCI Journal of the National Cancer Institute
Published
2010-06-18
Volume
102
Issue
13
Pages
950-958
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2154675718
Cited by
244
References
2
FWCI
26.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study. https://app.cochat.ai/papers/10.1093/jnci/djq154
The paper
Stattin, P., Holmberg, E., Johansson, J.-E., Holmberg, L., Adolfsson, J., Hugosson, J., & Sweden, O. B. O. T. N. P. C. R. (. O. (2010). Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djq154

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.